
Pharmaceutical Executive
The Pharm Exec Podcast goes beyond the pages of the Pharmaceutical Executive print magazine and http://PharmExec.com to bring the latest commercial insights to the C-suite through in-depth interviews. Podcast episodes examine current trends, key conferences, and critical topics in the industry.
Latest episodes

Apr 11, 2019 • 17min
Episode 29: Disease Prevention & Interception
Pharm Exec's European Editor, Julian Upton, caught up with Ben Wiegand, head of J&J's World Without Disease Accelerator unit, at eyeforpharma Barcelona. They talk about Wiegand's panel "Uniting Patients, Providers, and Payers to Bring Preventative Care to Life," and J&J's disease prevention and interception activities.
This podcast was brought to you by QxMD.

Mar 28, 2019 • 45min
Episode 28: Digital Medication
Michelle Maskaly and Christen Harm speak with Bill Carson, President & CEO of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and Kabir Nath, President & CEO of Otsuka North America Pharmaceuticals about digital medicine, mental health therapies, and creating a smooth and collaborative relationship between R&D and commercial.

Mar 15, 2019 • 23min
Episode 27: Sensitive Topics in Pharma
Pharm Exec editors talk with Seth Lederman, co-founder, CEO and chairman of Tonix Pharmaceuticals about how to navigate creating drugs for conditions such as PTSD and AIDS, running a business, and academia.

Mar 1, 2019 • 16min
Episode 26: Patient Advocacy
Pharm Exec editors sit down with Bob Ward, chairman and CEO of Eloxx Pharmaceuticals, to talk about his personal, as well as Eloxx’s, commitment to working with patient advocacy groups, how to attract talent, and how to put together a great team.

Feb 14, 2019 • 20min
Episode 25: China’s Pharma Growth
Michelle Maskaly and Christen Harm talk with David Shao, CEO of Yisheng Biopharma, about what’s driving China’s exploding pharma and biotech industries, as well as the country’s push to become a global life science leader.

Feb 5, 2019 • 26min
Episode 24: 2019 Industry Trends
Michelle Maskaly and Christen Harm sit down with Editor-in-Chief Lisa Henderson and European Editor Julian Upton to discuss the industry trends featured in Pharm Exec's January 2019 issue.

Jan 17, 2019 • 31min
Episode 23: Mindfulness in Clinical Trial R&D
Pharm Exec editors Michelle Maskaly and Christen Harm speak with Raymond Sanchez, senior vice president of Global Clinical Development at Otsuka Pharmaceutical Development & Commercialization. Raymond talks about his switch from academia to clinical development, the sobering affect of seeing a drug he helped develop on the pharmacy shelf, and how he uses mindfulness to encourage and lead his team.

Dec 13, 2018 • 20min
Episode 22: Virtual Reality and Marketing in Healthcare
Nicola Kayel, Vice President of Marketing at Salix Pharmaceuticals, speaks with Pharm Exec editors about the challenges and strategies for marketing drugs that treat embarrassing conditions, like irritable bowel syndrome. She also discusses the company's recent plunge into virtual and augmented reality and how it plays a role in the future for healthcare professionals.

Nov 29, 2018 • 32min
Episode 21: Southeast Biotech
Jack Bailey, president of US pharmaceuticals for GlaxoSmithKline, talks with Christen Harm and Michelle Maskaly, about the biopharma landscape in the southeastern part of the United States, as part of Pharm Exec’s ongoing series that looks at growing biotech innovation hubs across the country. Bailey gives unmatched insights about the efforts North Carolina has put into growing, attracting, and retaining life science startups, specifically in the Raleigh-Durham area, as well as addresses challenges such as access to venture capital.

Nov 8, 2018 • 28min
Episode 20: Analyzing the Pharma Pipeline
Pharm Exec Editorial Director Lisa Henderson and European Editor Julian Upton talk with Michelle Maskaly and Christen Harm about the magazine’s recent pharmaceutical pipeline report which was published in the November 2018 issue. Topics include cannabis, CAR-T therapy, opioids, biosimilars, and Alzheimer’s.